{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:22:20Z","timestamp":1792686140811,"version":"4.5.0"},"reference-count":76,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>The comparative effectiveness of specific antihypertensive agents in preventing new-onset or recurrent atrial fibrillation (AF) remains under debate. This study aimed to evaluate the impact of different antihypertensive agents on AF risk.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>Medline, Cochrane, EMBASE, and ClinicalTrials.gov databases were searched for randomized controlled trials (RCTs) reporting AF events as a predefined outcome. Angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), dihydropyridine calcium channel blockers (CCBs), \u03b2-blockers, mineralocorticoid antagonists (MRAs), and thiazide diuretics (TDs) were analyzed. The risk ratio (RR) with a 95% credible interval (CrI) was calculated within a Bayesian random-effects network meta-analysis (NMA). Treatments were ranked using the surface under the cumulative ranking (SUCRA). Twenty-two RCTs randomising 66,156 patients with hypertension, diabetes, or AF were included. ACE inhibitors plus TD (RR 0.44; 95% CrI 0.23\u20130.82), ACE inhibitors (RR 0.66; 95% CrI 0.44\u20130.95), and ARBs (RR 0.52; 95% CrI 0.38\u20130.70) were associated with lower rates of new-onset or recurrent AF compared with CCBs. SUCRA ranked ACE inhibitors plus TD (0.86) as the best, followed by ARBs (0.77), MRAs (0.75), and ACE inhibitors (0.53) for preventing AF events. These findings were consistent across secondary and sensitivity analyses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In this NMA comparing multiple antihypertensive regimens in patients with hypertension, diabetes, or AF, ACE inhibitors plus TD, ACE inhibitors, and ARBs were the most effective in reducing AF events, outperforming CCBs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Registration<\/jats:title>\n                  <jats:p>PROSPERO Database (CRD42024588765).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwaf335","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T10:51:32Z","timestamp":1751367092000},"source":"Crossref","is-referenced-by-count":6,"title":["Effect of antihypertensive agents on the risk of new-onset and recurrent atrial fibrillation: a Bayesian network meta-analysis of randomized controlled trials"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9393-2445","authenticated-orcid":false,"given":"Douglas Mesadri","family":"Gewehr","sequence":"first","affiliation":[{"name":"Postgraduate Program in Internal Medicine and Health Sciences, Federal University of Paran\u00e1 , Curitiba ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0918-6759","authenticated-orcid":false,"given":"Pedro E P","family":"Carvalho","sequence":"additional","affiliation":[{"name":"Center for Coronary Artery Disease, Minneapolis Heart Institute, Minneapolis ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9370-8722","authenticated-orcid":false,"given":"Felipe Villa","family":"Martignoni","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Texas Tech University Health Science Center , Lubbock ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5995-6179","authenticated-orcid":false,"given":"Alleh","family":"Nogueira","sequence":"additional","affiliation":[{"name":"Postgraduate Program in Cardiology, School of Medicine, Federal University of Rio Grande do Sul , Porto Alegre ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9379-8186","authenticated-orcid":false,"given":"Cintia","family":"Gomes","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, UCHealth Parkview Medical Center , Pueblo ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4805-0931","authenticated-orcid":false,"given":"Denilsa Dinis Pedro","family":"Navalha","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Nebraska Medical Center , Omaha ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9070-5685","authenticated-orcid":false,"given":"Jacqueline","family":"Pirez","sequence":"additional","affiliation":[{"name":"Division of Medicine, University of Cesumar , Maring\u00e1 ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5435-6158","authenticated-orcid":false,"given":"Lara Melo Soares Pinho","family":"de Carvalho","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Connecticut , Farmington ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8607-6302","authenticated-orcid":false,"given":"Yasmin Luz Lima","family":"de Mesquita","sequence":"additional","affiliation":[{"name":"Division of Medicine, Federal University of Rio de Janeiro , Maca\u00e9 ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7819-2400","authenticated-orcid":false,"given":"Marcelo Antonio Pinheiro","family":"Braga","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Federal University of Rio de Janeiro , Rio de Janeiro ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6887-9387","authenticated-orcid":false,"given":"Emilton Lima","family":"Junior","sequence":"additional","affiliation":[{"name":"Postgraduate Program in Internal Medicine and Health Sciences, Federal University of Paran\u00e1 , Curitiba ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"2025072307214868400_zwaf335-B1","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1186\/s12889-022-14403-2","article-title":"Global, regional, and national burden of disease study of atrial fibrillation\/flutter, 1990\u20132019: results from a global burden of disease study, 2019","volume":"22","author":"Li","year":"2022","journal-title":"BMC Public Health"},{"key":"2025072307214868400_zwaf335-B2","doi-asserted-by":"crossref","first-page":"E93","DOI":"10.1161\/CIR.0000000000001123","article-title":"Heart disease and stroke statistics\u20142023 update: a report from the American Heart Association","volume":"147","author":"Tsao","year":"2023","journal-title":"Circulation"},{"key":"2025072307214868400_zwaf335-B3","first-page":"27","volume-title":"Short Stay Management of Atrial Fibrillation","author":"Sieck","year":"2016"},{"key":"2025072307214868400_zwaf335-B4","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCRESAHA.117.311402","article-title":"Hypertension and atrial fibrillation: doubts and certainties from basic and clinical studies","volume":"122","author":"Verdecchia","year":"2018","journal-title":"Circ Res"},{"key":"2025072307214868400_zwaf335-B5","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/S0140-6736(18)32335-3","article-title":"Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"GBD 2017 DALYs and HALE Collaborators","year":"2018","journal-title":"Lancet"},{"issue":"23 Suppl 2","key":"2025072307214868400_zwaf335-B6","doi-asserted-by":"crossref","first-page":"ii14","DOI":"10.1093\/europace\/euaa426","article-title":"Antiarrhythmic drugs for atrial fibrillation: lessons from the past and opportunities for the future","volume":"23","author":"Heijman","year":"2021","journal-title":"Europace"},{"key":"2025072307214868400_zwaf335-B7","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/1755-5922.12073","article-title":"Effect of telmisartan on atrial fibrillation recurrences in patients with hypertension: a systematic review and meta-analysis","volume":"32","author":"Pan","year":"2014","journal-title":"Cardiovasc Ther"},{"key":"2025072307214868400_zwaf335-B8","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/europace\/euv021","article-title":"Effect of antihypertensive agents on risk of atrial fibrillation: a meta-analysis of large-scale randomized trials","volume":"17","author":"Emdin","year":"2015","journal-title":"Europace"},{"key":"2025072307214868400_zwaf335-B9","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1177\/1074248415619490","article-title":"Effects of RAAS blockers on atrial fibrillation prophylaxis: an updated systematic review and meta-analysis of randomized controlled trials","volume":"21","author":"Chaugai","year":"2016","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2025072307214868400_zwaf335-B10","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/eurheartj\/ehl484","article-title":"Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis","volume":"28","author":"Nasr","year":"2007","journal-title":"Eur Heart J"},{"key":"2025072307214868400_zwaf335-B11","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1016\/j.jacc.2004.11.070","article-title":"Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis","volume":"45","author":"Healey","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2025072307214868400_zwaf335-B12","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1097\/HJH.0000000000003278","article-title":"Hypertension and atrial fibrillation","volume":"40","author":"Middeldorp","year":"2022","journal-title":"J Hypertens"},{"key":"2025072307214868400_zwaf335-B13","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1161\/HYPERTENSIONAHA.117.08934","article-title":"Atrial fibrillation and hypertension","volume":"70","author":"Dzeshka","year":"2017","journal-title":"Hypertension"},{"key":"2025072307214868400_zwaf335-B14","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1161\/HYPERTENSIONAHA.120.14766","article-title":"Effect of intensive blood pressure lowering on the risk of atrial fibrillation","volume":"75","author":"Soliman","year":"2020","journal-title":"Hypertension"},{"key":"2025072307214868400_zwaf335-B15","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/pace.13311","article-title":"Uncontrolled blood pressure affects atrial remodeling and adverse clinical outcome in paroxysmal atrial fibrillation","volume":"41","author":"Kamioka","year":"2018","journal-title":"Pacing Clin Electrophysiol"},{"key":"2025072307214868400_zwaf335-B16","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jash.2016.05.007","article-title":"Is there an association between the prevalence of atrial fibrillation and severity and control of hypertension? The REasons for Geographic and Racial Differences in Stroke study","volume":"10","author":"Bhatt","year":"2016","journal-title":"J Am Soc Hypertens"},{"key":"2025072307214868400_zwaf335-B17","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1161\/HYPERTENSIONAHA.111.179713","article-title":"Upper normal blood pressures predict incident atrial fibrillation in healthy middle-aged men","volume":"59","author":"Grundvold","year":"2012","journal-title":"Hypertension"},{"key":"2025072307214868400_zwaf335-B18","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jash.2015.01.001","article-title":"Sustained pre\u2013hypertensive blood pressure and incident atrial fibrillation: the multi\u2013ethnic study of atherosclerosis","volume":"9","author":"O\u2019Neal","year":"2015","journal-title":"J Am Soc Hypertens"},{"key":"2025072307214868400_zwaf335-B19","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/ajh.2008.248","article-title":"Blood pressure control and risk of incident atrial fibrillation","volume":"21","author":"Thomas","year":"2008","journal-title":"Am J Hypertens"},{"key":"2025072307214868400_zwaf335-B20","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1161\/HYPERTENSIONAHA.123.21858","article-title":"Antihypertensive drugs for the prevention of atrial fibrillation: a drug target Mendelian randomization study","volume":"81","author":"Geurts","year":"2024","journal-title":"Hypertension"},{"key":"2025072307214868400_zwaf335-B21","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024)","author":"Higgins","year":"2024"},{"key":"2025072307214868400_zwaf335-B22","first-page":"1","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2025072307214868400_zwaf335-B23","doi-asserted-by":"publisher","DOI":"10.1145\/2601248.2601268","volume-title":"Proceedings of the 18th International Conference on Evaluation and Assessment in Software Engineering","author":"Wohlin","year":"2014"},{"key":"2025072307214868400_zwaf335-B24","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"Rob 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2025072307214868400_zwaf335-B25","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"2025072307214868400_zwaf335-B26","volume-title":"GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations","author":"Sch\u00fcnemann","year":"2013"},{"key":"2025072307214868400_zwaf335-B27","doi-asserted-by":"crossref","first-page":"e074495","DOI":"10.1136\/bmj-2022-074495","article-title":"A guide and pragmatic considerations for applying GRADE to network meta-analysis","volume":"381","author":"Izcovich","year":"2023","journal-title":"BMJ"},{"key":"2025072307214868400_zwaf335-B28","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons","volume":"23","author":"Lu","year":"2004","journal-title":"Stat Med"},{"key":"2025072307214868400_zwaf335-B29","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/0272989X12458724","article-title":"Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials","volume":"33","author":"Dias","year":"2013","journal-title":"Med Decis Making"},{"key":"2025072307214868400_zwaf335-B30","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1177\/0272989X13487257","article-title":"Evidence synthesis for decision making 6: embedding evidence synthesis in probabilistic cost-effectiveness analysis","volume":"33","author":"Dias","year":"2013","journal-title":"Med Decis Making"},{"key":"2025072307214868400_zwaf335-B31","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat Med"},{"key":"2025072307214868400_zwaf335-B32","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"2025072307214868400_zwaf335-B33","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1214\/ss\/1177011136","article-title":"Inference from iterative simulation using multiple sequences","volume":"7","author":"Gelman","year":"1992","journal-title":"Statist Sci"},{"key":"2025072307214868400_zwaf335-B34","author":"R Core Team"},{"key":"2025072307214868400_zwaf335-B35","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Ment Health"},{"key":"2025072307214868400_zwaf335-B36","author":"van Valkenhoef"},{"key":"2025072307214868400_zwaf335-B37","author":"Plummer"},{"key":"2025072307214868400_zwaf335-B38","author":"Harrer"},{"key":"2025072307214868400_zwaf335-B39","author":"Tianqi"},{"key":"2025072307214868400_zwaf335-B40","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/FJC.0b013e318160b42a","article-title":"Comparative evaluation of effect of valsartan\/amlodipine and atenolol\/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus","volume":"51","author":"Fogari","year":"2008","journal-title":"J Cardiovasc Pharmacol"},{"key":"2025072307214868400_zwaf335-B41","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jacc.2004.10.068","article-title":"Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the losartan intervention for end point reduction in hypertension (LIFE) study","volume":"45","author":"Wachtell","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2025072307214868400_zwaf335-B42","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1056\/NEJMoa1008816","article-title":"Irbesartan in patients with atrial fibrillation","volume":"364","author":"ACTIVE I Investigators","year":"2011","journal-title":"N Engl J Med"},{"key":"2025072307214868400_zwaf335-B43","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/europace\/euq439","article-title":"Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study)","volume":"13","author":"Yamashita","year":"2011","journal-title":"Europace"},{"key":"2025072307214868400_zwaf335-B44","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jjcc.2017.07.010","article-title":"Study on the effect of irbesartan on atrial fibrillation recurrence in kumamoto: atrial fibrillation suppression trial (SILK study)","volume":"71","author":"Yamabe","year":"2018","journal-title":"J Cardiol"},{"key":"2025072307214868400_zwaf335-B45","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/HJH.0b013e3282f35c67","article-title":"Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial","volume":"26","author":"Schmieder","year":"2008","journal-title":"J Hypertens"},{"key":"2025072307214868400_zwaf335-B46","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.ahj.2007.04.062","article-title":"Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study","volume":"154","author":"Salehian","year":"2007","journal-title":"Am Heart J"},{"key":"2025072307214868400_zwaf335-B47","first-page":"1651","article-title":"Effects of telmisartan on paroxysmal atrial fibrillation in hypertensive patients","volume":"30","author":"Li","year":"2017","journal-title":"Pak J Pharm Sci"},{"key":"2025072307214868400_zwaf335-B48","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.cjco.2021.04.014","article-title":"Effect of perindopril on atrial fibrillation recurrence and burden: results of the Canadian trial of atrial fibrillation (CTAF)-2","volume":"3","author":"Rivard","year":"2021","journal-title":"CJC Open"},{"key":"2025072307214868400_zwaf335-B49","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1161\/CIRCEP.111.965178","article-title":"Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial","volume":"5","author":"Goette","year":"2012","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2025072307214868400_zwaf335-B50","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1177\/1470320312443909","article-title":"A multicentre, randomized study of telmisartan versus carvedilol for prevention of atrial fibrillation recurrence in hypertensive patients","volume":"13","author":"Galzerano","year":"2012","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"2025072307214868400_zwaf335-B51","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/clc.21994","article-title":"Effect of telmisartan on paroxysmal atrial fibrillation recurrence in hypertensive patients with normal or increased left atrial size","volume":"35","author":"Fogari","year":"2012","journal-title":"Clin Cardiol"},{"key":"2025072307214868400_zwaf335-B52","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/1074248410395018","article-title":"Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation","volume":"17","author":"Fogari","year":"2012","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2025072307214868400_zwaf335-B53","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/ajh.2008.217","article-title":"Effect of valsartan and ramipril on atrial fibrillation recurrence and p-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation","volume":"21","author":"Fogari","year":"2008","journal-title":"Am J Hypertens"},{"key":"2025072307214868400_zwaf335-B54","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jacc.2021.04.079","article-title":"Finerenone reduces new-onset atrial fibrillation in patients with chronic kidney disease and type 2 diabetes","volume":"78","author":"Filippatos","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2025072307214868400_zwaf335-B55","doi-asserted-by":"crossref","first-page":"e005463","DOI":"10.1161\/CIRCEP.117.005463","article-title":"Pharmacologic prevention of incident atrial fibrillation: long-term results from the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial)","volume":"10","author":"Dewland","year":"2017","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2025072307214868400_zwaf335-B56","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1161\/HYPERTENSIONAHA.111.202309","article-title":"Effect of nifedipine versus telmisartan on prevention of atrial fibrillation recurrence in hypertensive patients","volume":"61","author":"Du","year":"2013","journal-title":"Hypertension"},{"key":"2025072307214868400_zwaf335-B57","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/eurheartj\/ehp055","article-title":"Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study","volume":"30","author":"Du","year":"2009","journal-title":"Eur Heart J"},{"key":"2025072307214868400_zwaf335-B58","doi-asserted-by":"crossref","first-page":"631","DOI":"10.3892\/etm.2014.2143","article-title":"Effect of valsartan on atrial fibrillation recurrence following pulmonary vein isolation in patients","volume":"9","author":"Cui","year":"2015","journal-title":"Exp Ther Med"},{"key":"2025072307214868400_zwaf335-B59","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/clc.4960280609","article-title":"The comparative effects of telmisartan and ramipril on P-wave dispersion in hypertensive patients: a randomized clinical study","volume":"28","author":"Celik","year":"2005","journal-title":"Clin Cardiol"},{"key":"2025072307214868400_zwaf335-B60","doi-asserted-by":"crossref","first-page":"550","DOI":"10.5114\/aoms.2016.62448","article-title":"Effect of ramipril\/hydrochlorothiazide and ramipril\/canrenone combination on atrial fibrillation recurrence in hypertensive type 2 diabetic patients with and without cardiac autonomic neuropathy","volume":"13","author":"Bosone","year":"2017","journal-title":"Arch Med Sci"},{"key":"2025072307214868400_zwaf335-B61","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jacc.2008.08.071","article-title":"Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients","volume":"53","author":"Belluzzi","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2025072307214868400_zwaf335-B62","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"2025072307214868400_zwaf335-B63","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41572-022-00347-9","article-title":"Atrial fibrillation","volume":"8","author":"Brundel","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"2025072307214868400_zwaf335-B64","doi-asserted-by":"publisher","DOI":"10.5772\/53917","volume-title":"Atrial Fibrillation\u2014Mechanisms and Treatment","author":"Perlini","year":"2013"},{"key":"2025072307214868400_zwaf335-B65","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/j.jacc.2010.01.043","article-title":"Prevention of atrial fibrillation by renin-angiotensin system inhibition","volume":"55","author":"Schneider","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2025072307214868400_zwaf335-B66","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jacep.2015.04.002","article-title":"Impact of uncontrolled hypertension on atrial fibrillation ablation outcome","volume":"1","author":"Santoro","year":"2015","journal-title":"JACC Clin Electrophysiol"},{"key":"2025072307214868400_zwaf335-B67","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1161\/CIRCULATIONAHA.108.830042","article-title":"Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women","volume":"119","author":"Conen","year":"2009","journal-title":"Circulation"},{"key":"2025072307214868400_zwaf335-B68","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.amjcard.2014.05.041","article-title":"Relation of systolic, diastolic, and pulse pressures and aortic distensibility with atrial fibrillation (from the Multi-Ethnic Study of Atherosclerosis)","volume":"114","author":"Roetker","year":"2014","journal-title":"Am J Cardiol"},{"key":"2025072307214868400_zwaf335-B69","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10654-022-00914-0","article-title":"Blood pressure, hypertension and the risk of atrial fibrillation: a systematic review and meta-analysis of cohort studies","volume":"38","author":"Aune","year":"2023","journal-title":"Eur J Epidemiol"},{"key":"2025072307214868400_zwaf335-B70","doi-asserted-by":"crossref","first-page":"1372505","DOI":"10.3389\/fcvm.2024.1372505","article-title":"Association between types of antihypertensive medication and the risk of atrial fibrillation: a nationwide population study","volume":"11","author":"Choi","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"2025072307214868400_zwaf335-B71","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s40256-016-0173-4","article-title":"Unraveling the pivotal role of bradykinin in ACE inhibitor activity","volume":"16","author":"Taddei","year":"2016","journal-title":"Am J Cardiovasc Drugs"},{"key":"2025072307214868400_zwaf335-B72","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.pcad.2016.10.002","article-title":"Renin angiotensin aldosterone system inhibitors in hypertension: is there evidence for benefit independent of blood pressure reduction?","volume":"59","author":"Bavishi","year":"2016","journal-title":"Prog Cardiovasc Dis"},{"key":"2025072307214868400_zwaf335-B73","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1161\/HYPERTENSIONAHA.120.16667","article-title":"Comparative first-line effectiveness and safety of ACE (Angiotensin-Converting Enzyme) inhibitors and angiotensin receptor blockers: a multinational cohort study","volume":"78","author":"Chen","year":"2021","journal-title":"Hypertension"},{"key":"2025072307214868400_zwaf335-B74","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)","volume":"288","author":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group","year":"2002","journal-title":"JAMA"},{"key":"2025072307214868400_zwaf335-B75","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.amjms.2024.07.016","article-title":"Meta-analysis of renin angiotensin aldosterone modulators mitigating Atrial Fibrillation risk in hypertensive patients","volume":"368","author":"Mahadevan","year":"2024","journal-title":"Am J Med Sci"},{"key":"2025072307214868400_zwaf335-B76","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/ijcp.12063","article-title":"Renin-angiotensin system inhibitors for prevention of recurrent atrial fibrillation: a meta-analysis","volume":"67","author":"Li","year":"2013","journal-title":"Int J Clin Pract"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwaf335\/63636876\/zwaf335.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwaf335\/63636876\/zwaf335.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T11:22:05Z","timestamp":1753269725000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article\/doi\/10.1093\/eurjpc\/zwaf335\/8180368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":76,"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwaf335","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"article-number":"zwaf335"}}